Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s Disease in 204 Countries/Territories from 1990 to 2019. Front Public Health. 2021;9:776847.

Article  PubMed  PubMed Central  Google Scholar 

Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson Disease. CMAJ. 2016;188:1157–65.

Article  PubMed  PubMed Central  Google Scholar 

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s Disease. Lancet Neurol. 2021;20:385–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jankovic J. Parkinson’s Disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–76.

Article  CAS  PubMed  Google Scholar 

Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson Disease and the neurobiology of axons. Ann Neurol. 2010;67:715–25.

Article  PubMed  PubMed Central  Google Scholar 

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–40.

Article  CAS  PubMed  Google Scholar 

Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s Disease. Lancet. 2004;364:1169–71.

Article  CAS  PubMed  Google Scholar 

Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s Disease. Lancet. 2004;364:1167–9.

Article  CAS  PubMed  Google Scholar 

Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. Alpha-synuclein locus triplication causes Parkinson’s Disease. Science. 2003;302:841.

Article  CAS  PubMed  Google Scholar 

Liu H, Koros C, Strohaker T, Schulte C, Bozi M, Varvaresos S, Ibanez de Opakua A, Simitsi AM, Bougea A, Voumvourakis K, et al. A novel SNCA A30G mutation causes familial Parkinson’s Disease. Mov Disord. 2021;36:1624–33.

Article  CAS  PubMed  Google Scholar 

Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s Disease. Nat Genet. 1998;18:106–8.

Article  CAS  PubMed  Google Scholar 

Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body Dementia. Ann Neurol. 2004;55:164–73.

Article  CAS  PubMed  Google Scholar 

Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s Disease. Mov Disord. 2013;28:811–3.

Article  CAS  PubMed  Google Scholar 

Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel alpha-synuclein missense mutation in Parkinson Disease. Neurology. 2013;80:1062–4.

Article  PubMed  PubMed Central  Google Scholar 

Lesage S, Anheim M, Letournel F, Bousset L, Honore A, Rozas N, Pieri L, Madiona K, Durr A, Melki R, et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73:459–71.

Article  CAS  PubMed  Google Scholar 

Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, et al. Alpha-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s Disease and Multiple System Atrophy? Acta Neuropathol. 2013;125:753–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s Disease. Science. 1997;276:2045–7.

Article  CAS  PubMed  Google Scholar 

Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, Poyhonen M, Paetau A. Novel alpha-synuclein mutation A53E associated with atypical Multiple System Atrophy and Parkinson’s disease-type pathology. Neurobiol Aging. 2014;35:2180e2181–2185.

Article  Google Scholar 

Martikainen MH, Paivarinta M, Hietala M, Kaasinen V. Clinical and imaging findings in Parkinson Disease associated with the A53E SNCA mutation. Neurol Genet. 2015;1:e27.

Article  PubMed  PubMed Central  Google Scholar 

Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, et al. Homozygous alpha-synuclein p.A53V in familial Parkinson’s Disease. Neurobiol Aging. 2017;57:248. e247-248 e212.

Article  Google Scholar 

Kapasi A, Brosch JR, Nudelman KN, Agrawal S, Foroud TM, Schneider JA. A novel SNCA E83Q mutation in a case of Dementia with Lewy bodies and atypical frontotemporal lobar degeneration. Neuropathology. 2020;40:620–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conway KA, Harper JD, Lansbury PT Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson’s Disease are typical amyloid. Biochemistry. 2000;39:2552–63.

Article  CAS  PubMed  Google Scholar 

Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem. 2005;280:7800–7.

Article  CAS  PubMed  Google Scholar 

Ghosh D, Mondal M, Mohite GM, Singh PK, Ranjan P, Anoop A, Ghosh S, Jha NN, Kumar A, Maji SK. The Parkinson’s disease-associated H50Q mutation accelerates alpha-synuclein aggregation in vitro. Biochemistry. 2013;52:6925–7.

Article  CAS  PubMed  Google Scholar 

Rutherford NJ, Moore BD, Golde TE, Giasson BI. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J Neurochem. 2014;131:859–67.

Article  CAS  PubMed  Google Scholar 

Li Y, Zhao C, Luo F, Liu Z, Gui X, Luo Z, Zhang X, Li D, Liu C, Li X. Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy. Cell Res. 2018;28:897–903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerrero-Ferreira R, Taylor NM, Arteni AA, Kumari P, Mona D, Ringler P, Britschgi M, Lauer ME, Makky A, Verasdonck J et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. Elife 2019, 8.

Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinson’s disease - lessons and emerging principles. Mol Neurodegeneration 2019, 14.

Sulzer D, Edwards RH. The physiological role of alpha-synuclein and its relationship to Parkinson’s Disease. J Neurochem. 2019;150:475–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE. Alpha-synuclein-based animal models of Parkinson’s Disease: challenges and opportunities in a new era. Trends Neurosci. 2016;39:750–62.

Article  CAS  PubMed  Google Scholar 

Klein C, Westenberger A. Genetics of Parkinson’s Disease. Cold Spring Harb Perspect Med. 2012;2:a008888.

Article  PubMed  PubMed Central  Google Scholar 

Rocha EM, Keeney MT, Di Maio R, De Miranda BR, Greenamyre JT. LRRK2 and idiopathic Parkinson’s Disease. Trends Neurosci. 2022;45:224–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge P, Dawson VL, Dawson TM. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s Disease. Mol Neurodegener. 2020;15:20.

Article  PubMed  PubMed Central  Google Scholar 

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C. Movement Disorder Society Evidence-Based Medicine C: International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s Disease. Mov Disord. 2018;33:1248–66.

Article  CAS  PubMed  Google Scholar 

Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting alpha-synuclein for Parkinson’s Disease. Pharmacol Rev. 2022;74:207–37.

Article  PubMed  Google Scholar 

Mason JM. Design and development of peptides and Peptide Mimetics as antagonists for therapeutic intervention. Future Med Chem. 2010;2:1813–22.

Article  CAS  PubMed  Google Scholar 

Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based Drugs. Chem Biol Drug Des. 2013;81:136–47.

Article